Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Dextromethorphan

Dextromethorphan

Dextromethorphan is a synthetic, non-opioid cough suppressant with dissociative properties.
It acts as an NMDA receptor antagonist, modulating glutamatergic neurotransmission and producing psychoactive effects.
Reserach into dextromethorphan's therapeutic applications and mechanisms of action is facilitated by PubCompare.ai, an AI-driven platform that helps locate and compare protocols from literature, preprints, and patents.
This tool can identify the most accurate and effecitve dextromethorphan protocols, streamlining the research process and enabling researchers to find the best dextromethorphan products.

Most cited protocols related to «Dextromethorphan»

1
Cytochrome P450 Mediated Metabolism
Cited 18 times
Tolbutamide was purchased from Dr. Ehrenstorfer GmbH (Augsburg, Germany). 4-hydroxyTolbutamide and 6-hydroxychlorzoxazone were obtained from Toronto Research Chemicals Inc. (North York, Canada). Dextromethorphan, dextrorphan and chlorzoxazone were supplied by Sigma-Aldrich Co. (St Louis, MO, USA). Testosterone was obtained from International Laboratory Limited (San Bruno, CA, USA). 6β-hydroxytestosterone was purchased from BD Biosciences Co. (Woburn, MA, USA). Phenacetin, cortisone acetate, EB and EE were from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). NADPH was obtained from Roche Diagnostics GmbH (Mannheim, Germany). All other reagents were of HPLC or analytical grade.
Guo S., Liu Y., Lin Z., Tai S., Yin S, & Liu G. (2014). Effects of Eleutheroside B and Eleutheroside E on activity of cytochrome P450 in rat liver microsomes. BMC Complementary and Alternative Medicine, 14, 1.
Full text: Click here
Publication 2014
4'-hydroxytolbutamide 6-hydroxychlorzoxazone Biological Products Chlorzoxazone Cortisone Acetate Dextromethorphan Dextrorphan Diagnosis High-Performance Liquid Chromatographies NADP Pharmaceutical Preparations Phenacetin Testosterone Tolbutamide
2
Pharmacokinetic Interaction Study of MDMA and Duloxetine
Cited 7 times
Sixteen healthy subjects (eight men, eight women) with a mean±SD age of 26.1±6.0 years participated in the study. The allocation to treatment order was performed by drawing from blocks of eight different balanced drug treatment sequences by a pharmacist not involved in the study. Each code was stored in a sealed envelope until the termination of the study. Data from all 16 subjects were available for the final analysis (Figure 1). The sample-size estimation showed that 13 subjects would be needed to detect a meaningful reduction of 20% of the MDMA drug effect by duloxetine with more than 80% power using a within-subjects study design. The exclusion criteria included the following; (i) age <18 or >45 years, (ii) pregnancy determined by a urine test before each session, (iii) body mass index <18.5 kg/m2 or >25 kg/m2, (iv) personal or family (first-degree relative) history of psychiatric disorder (determined by the structured clinical interview of Axis I and Axis II disorders according the Diagnostic and Statistical Manual of Mental Disorders, 4th edition [18] supplemented by the SCL-90-R Symptom Checklist [19] (link), [20] (link)
(v) regular use of medications, (vi) chronic or acute physical illness assessed by physical examination, electrocardiogram, standard hematological, and chemical blood analyses, (vii) smoking more than 10 cigarettes per day, (viii) a lifetime history of using illicit drugs more than five times with the exception of cannabis, (ix) illicit drug use within the last 2 months, and (x) illicit drug use during the study determined by urine tests conducted before the test sessions. None of the 16 subjects had used ecstasy previously. The subjects were asked to abstain from excessive alcohol consumption between the test sessions and limit their alcohol use to one glass on the day before the test session. All of the subjects were phenotyped for cytochrome P450 (CYP) 2D6 activity using dextromethorphan. Thirteen extensive, two intermediate, and one poor CYP 2D6 metabolizer were identified in the study. The female subjects were investigated during the follicular phase (day 2–14) of their menstrual cycle.
Hysek C.M., Simmler L.D., Nicola V.G., Vischer N., Donzelli M., Krähenbühl S., Grouzmann E., Huwyler J., Hoener M.C, & Liechti M.E. (2012). Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study. PLoS ONE, 7(5), e36476.
Full text: Click here
Publication 2012
BLOOD Cannabis Cytochrome P-450 CYP2D6 Dextromethorphan Duloxetine Electrocardiography Epistropheus Females Healthy Volunteers Illicit Drugs Index, Body Mass MDMA Menstrual Cycle Menstrual Cycle, Proliferative Phase Mental Disorders Pharmaceutical Preparations Physical Examination Pregnancy Urinalysis Woman
3
Evaluation of CYP Isoform Activity
Cited 7 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Acids Biological Assay Buffers Bupropion Cells Chlorzoxazone Culture Media CYP1A2 protein, human CYP2C19 protein, human Cytochrome P-450 CYP2D6 Cytochrome P-450 CYP2E1 Cytochrome P-450 CYP3A4 Dextromethorphan Diagnosis Diclofenac Egtazic Acid Glycerin Hepatocyte HEPES Homo sapiens Liver Magnesium Chloride Mephenytoin Midazolam Pellets, Drug Phenacetin Phosphates Protease Inhibitors Proteins Saline Solution Sodium Chloride Tablet Triton X-100
4
Michaelis Constant and Reaction Velocity
Cited 6 times
The apparent Km (Michaelis constant) and Vmax (maximum reaction velocity) values were determined in a range of concentrations of probe drugs. The concentrations were as follows: tolbutamide 3.5~600.0 μM, dextromethorphan 3.5~400.0 μM, chlorzoxazone 5.0~300.0 μM, and testosterone 12.5~500.0 μM. The other incubation conditions were the same as Section Cytochrome P450 probe substrate assays.
Guo S., Liu Y., Lin Z., Tai S., Yin S, & Liu G. (2014). Effects of Eleutheroside B and Eleutheroside E on activity of cytochrome P450 in rat liver microsomes. BMC Complementary and Alternative Medicine, 14, 1.
Full text: Click here
Publication 2014
Biological Assay Chlorzoxazone Cytochrome P450 Dextromethorphan Pharmaceutical Preparations Testosterone Tolbutamide
5
Analytical Methodology for Pharmacokinetic Biomarkers
Cited 4 times
All reference materials were obtained from Sigma Aldrich, St Louis, MO, Toronto Research Chemicals, North York Ontario CA, and Cerilliant, Round Rock, TX, except norfluoxetine stereoisomers which were synthesized in house(3 (link)). Concentrations of omeprazole, 5-hydroxyomeprazole, dextromethorphan, dextrorphan, dextrorphan-O-glucuronide, midazolam and caffeine in plasma and urine were analyzed using a Shimadzu Prominence UHPLC (Tokyo, Japan) coupled to an AB Sciex API3200 MS/MS (Framingham, MA) as described previously (3 (link), 22 (link)). Cortisol, cortisone, 6β-hydroxycortisol, 6β-hydroxycortisone, lovastatin and hydroxylovastatin acid were analyzed using an Agilent 1290 UHPLC (Santa Clara, CA) coupled to an AB Sciex API5500 MS/MS. Analytes were separated using a Thermo Hypersil Gold 100x2.1mm, 1.9µm column (West Palm Peach, FL) with a gradient elution from 90% water with 0.1% formic acid:10% acetonitrile (0.5 min), to 90% acetonitrile by 3.5 minutes, held until 5 min, then allowed to re-equilibrate to initial conditions until 7 minutes. The (R)- and (S)- enantiomers of fluoxetine and norfluoxetine were separated using an Astec Chirobiotic V 250x2.1mm, 5µm (St. Louis, MO) column and isocratic elution with 10% water and 90% methanol with 10mM ammonium formate. All analytes were detected using positive electrospray ionization except for dextrorphan-O-glucuronide, 6β-hydroxycortisol, 6β-hydroxycortisone and hydroxylovastatin acid, which were detected using negative electrospray ionization. All MRM transitions (m/z) were as previously described (22 (link)) except the following: 272→128 (dextromethorphan), 258→157 (dextrorphan), 432→256 (dextrorphan-O-glucuronide), 195→138 (caffeine), 363→121 (cortisol), 361→163 (cortisone), 423→347 (6β-hydroxycortisol), 421→345 (6β-hydroxycortisone), 427→325 (lovastatin) and 421→319 (hydroxylovastatin acid). The injection volume for all assays was 10µL. The lower limits of quantitation were less than 1nM for all analytes, except for caffeine (15nM). Inter-day percent coefficient of variation for all analytes at 1nM (30nM for caffeine) was less than 15%. All samples were protein precipitated with 1:2 sample:acetonitrile, except omeprazole and 5-hydroxyomeprazole (2:3:1 sample:acetonitrile:methanol), centrifuged twice at 3000g for 15min and the supernatant was used for analysis. The organic solvent contained 100nM of d3-omeprazole, d4-midazolam, d6-fluoxetine or simvastatin as internal standards. Cortisol, cortisone, 6β-hydroxycortisol and 6β-hydroxycortisone were extracted from the 6 hr plasma sample and the 0–12 hr urine sample from control day 3 and study day 14 using a previously described liquid-liquid extraction method (23 (link)) with the addition of a second extraction and using the internal standard of 100nM 16β-methylprednisolone.
Sager J.E., Lutz J.D., Foti R.S., Davis C., Kunze K.L, & Isoherranen N. (2014). Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4. Clinical pharmacology and therapeutics, 95(6), 653-662.
Publication 2014
5-hydroxymethylomeprazole acetonitrile Acids Arecaceae ARID1A protein, human Biological Assay Caffeine Cortisone Dextromethorphan Dextrorphan Fluoxetine formic acid formic acid, ammonium salt Glucuronides Gold Hydrocortisone Liquid-Liquid Extraction Lovastatin Methanol Methylprednisolone Midazolam norfluoxetine Omeprazole Plasma Proteins Prunus persica Simvastatin Solvents Stereoisomers Tandem Mass Spectrometry Urine

Most recents protocols related to «Dextromethorphan»

1
Compatibility Study of Liquisoft Excipient Formula
Not available on PMC !

Example 10

Formula 19 was used for excipient compatibility studies at stressed conditions (60° C. for 2 weeks) and the results are recorded in Table 12. A 3% loss occurred in the sample taken on the day of fill compounding and a 3% menthol loss occurred by the time the fill was encapsulated.

TABLE 12
Exemplary Liquisoft Composition
Formula 19Assay
(Talin-basedDextromethorphan
fill)HBrMentholDegradation Products
T099.9%97.4%Dextromethorphan: 0.01%
1 week at100.0%95.0%Dextromethorphan: 0.01%
60° C.RRT 0.95: 0.03%
2 weeks at99.7%93.5%Dextromethorphan: 0.01%
60° C.RRT 0.95: 0.03%

US11872307B2. Liquisoft capsules (2024-01-16). PATHEON SOFTGELS INC. [US]. Inventors: YinYan Zhao [US], Yunhua Hu [US], Mervin Williams, Jr. [US], Tatyana Dyakonov [US], Saujanya Gosangari [US], Chue Yang [US], Henricus Marinus Gerardus Maria Van Duijnhoven [NL], Martin Piest [NL], Aqeel A. Fatmi [US].
Full text: Click here
Patent 2024
Biological Assay Capsule Dextromethorphan Excipients Menthol Stress Disorders, Traumatic Talin
2
Investigating BI 425809's CYP Inhibition
To investigate the potential of BI 425809 to reversibly inhibit the major human CYPs, CYP-selective substrates (phenacetin 60 μM [CYP1A2], bupropion 80 μM [CYP2B6], amodiaquine 2 μM [CYP2C8], diclofenac 5 μM [CYP2C9], S-mephenytoin 80 μM [CYP2C19], dextromethorphan 5 μM [CYP2D6], midazolam 2 μM, and testosterone 50 μM [CYP3A4/5]) were incubated with human liver microsomes and BI 425809 (0.015, 0.046, 0.137, 0.411, 1.23, 3.70, 11.1, 33.3, and 100 μM). For positive control reactions, BI 425809 was replaced with a CYP-selective inhibitor (α-naphthoflavone [CYP1A2], ticlopidine [CYP2B6], montelukast [CYP2C8], sulfaphenazole [CYP2C9], benzylnirvanol [CYP2C19], quinidine [CYP2D6], and itraconazole [CYP3A4/5]). Substrate metabolites were quantified with liquid chromatography–tandem mass spectrometry using gradient elution (mobile phase for amodiaquine metabolite—A, 5 mM ammonium formate in water/formic acid [100:0.1, v/v]; B, acetonitrile/formic acid [100:0.1, v/v]; mobile phase for all other substrate metabolites—A, water/formic acid [100:0.1, v/v]; B, acetonitrile/formic acid [100:0.1, v/v]) on a Synergi Hydro RP column (50 × 2.0 mm, 4 μm; Phenomenex) with positive electrospray ionization.
IC50 values were obtained using a 3-parameter dose-response, 4-parameter dose-response, or normalized dose-response model; model comparisons were performed in Prism 6 (GraphPad Inc) to determine the optimal model for each data set. A least-squares fitting approach was used, and the Hill slope was not constrained for the 4-parameter model.
Desch M., Schlecker C., Hohl K., Liesenfeld K.H., Chan T., Müller F., Wunderlich G., Keller S., Ishiguro N, & Wind S. (2023). Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study. Journal of Clinical Psychopharmacology, 43(2), 113-121.
Publication 2023
acetonitrile Amodiaquine BI 425809 Bupropion Cardiac Arrest CYP1A2 protein, human CYP2C8 protein, human CYP2C19 protein, human Cytochrome P-450 CYP2D6 Cytochrome P-450 CYP3A4 Dextromethorphan Diclofenac formic acid formic acid, ammonium salt Homo sapiens Itraconazole Liquid Chromatography Mephenytoin Microsomes, Liver Midazolam montelukast Phenacetin prisma Quinidine Sulfaphenazole Tandem Mass Spectrometry Testosterone Ticlopidine
3
Cytochrome P450 Inhibition Assay
The experiments were classified into six groups (n = 3): control (no inhibitor), positive inhibitor, SZ-A (final concentration, 8.899 μg/mL; equivalent to 20 μM DNJ), DNJ (final concentration, 20 μM), FA (final concentration, 5 μM), and DAB (final concentration, 8 μM). Different inhibitors were added to the HLMs/RLMs and incubated with the probe substrates of each subtype.
The liver microsomal incubation system comprised human or rat liver microsomal protein (0.5 mg/mL), nicotinamide adenine dinucleotide phosphate (NADPH) generation system, Tris-HCl buffer (50 mM, pH 7.4), substrate, and inhibitor, with a total reaction volume of 200 μL. The substrate concentrations and incubation times for CYP1A2, 2D6/2D2, 2C9/2C6, 2C19/2C11, 3A4/3A2, and 2E1 were phenacetins, 50 μM/30 min; dextromethorphan, 5 μM/10 min; diclofenac sodium, 20 μM/10 min; mephenytoin, 40 μM/30 min; midazolam, 5 μM/5 min; and chlorzoxazone, 80 μM/20 min, respectively. The concentrations of each isoenzyme-positive inhibitor were 10 μM of furafylline (50 μM in the rat group), 2 μM quinidine (25 μM in the rat group), 5 μM sulfaphenazole (50 μM in the rat group), 5 μM of diclofenac pyridine (25 μM in the rat group), 1 μM ketoconazole, and 80 μM sodium diethyldithiacarbamate (100 μM in the rat group). After the reaction was completed, 400 μL of the internal standard propranolol (final concentration, 200 ng/mL) in ice-cold acetonitrile was added to terminate the reaction, and the sample was mixed well and centrifuged twice at 14,000 rpm for 5 min. Five microliters of the supernatant were collected for LC-MS/MS analysis (UPLC-Q-Extractive Orbitrap MS; Thermo Fisher Scientific, Waltham, MA, United States) to determine the metabolite content of the probe substrate.
Liu Z., Feng Y., Zhao H., Hu J., Chen Y., Liu D., Wang H., Zhu X., Yang H., Shen Z., Xia X., Ye J, & Liu Y. (2023). Pharmacokinetics and tissue distribution of Ramulus Mori (Sangzhi) alkaloids in rats and its effects on liver enzyme activity. Frontiers in Pharmacology, 14, 1136772.
Full text: Click here
Publication 2023
acetonitrile Chlorzoxazone Cold Temperature Cytochrome P-450 CYP1A2 Dextromethorphan Diclofenac Diclofenac Sodium Exhaling furafylline inhibitors Isoenzymes Ketoconazole Mephenytoin Microsomes Microsomes, Liver Midazolam NADP NR4A2 protein, human Portal System Propranolol pyridine Quinidine Sodium Sulfaphenazole Tandem Mass Spectrometry Tromethamine
4
Characterization of Phytochemicals in SZ-A Extract
DNJ (purity >99.0%) and SZ-A extract (Lot No.: J202004007, containing 36.88% of DNJ, 8.78% of FA, and 5.83% of DAB; Lot No.: J202108007, containing 36.52% of DNJ, 9.60% of FA, and 7.62% of DAB) were provided by Beijing Wehand-bio Pharmaceutical Co. Ltd. (Beijing, China). The multiple reaction monitoring (MRM) chromatogram of SZ-A is shown in Supplementary Figure S1. Miglitol was obtained from TCI Shanghai Chemical Industrial Development Co., Ltd. (Shanghai, China). FA (purity >98.0%) was purchased from MedChemExpress (Monmouth Junction, NJ, United States ). DAB (purity >98.0%) was purchased from Sigma-Aldrich (St. Louis, MO, United States ). Human liver microsomes (HLMs) were purchased from Reid Liver Disease Research (Shanghai, China). Glucose-6-phosphate, oxidized coenzyme H (β-NADP), Glucose-6-phosphate dehydrogenase, midazolam, phenacetin, dextromethorphan, mephenytoin, chlorzoxazone, diclofenac sodium, 1-Hydroxy-midazolam, 4-hydroxy-mephenytoin, acetaminophen, 4-Hydroxy-diclofenac sodium, demethyldextromethorphan, 6-Hydroxy-chlorzoxazone, furaphylline, sulfafenpyrazole, quinidine, ketoconazole, and sodium diethyldithiacarbamate were purchased from Sigma-Aldrich (St. Louis, MO, United States ). All other organic reagents were of analytical grade and purchased from Sinopharm Chemical Reagent (Shanghai, China).
Liu Z., Feng Y., Zhao H., Hu J., Chen Y., Liu D., Wang H., Zhu X., Yang H., Shen Z., Xia X., Ye J, & Liu Y. (2023). Pharmacokinetics and tissue distribution of Ramulus Mori (Sangzhi) alkaloids in rats and its effects on liver enzyme activity. Frontiers in Pharmacology, 14, 1136772.
Full text: Click here
Publication 2023
4'-hydroxydiclofenac Acetaminophen Chlorzoxazone Coenzymes Dextromethorphan Diclofenac Sodium Glucose-6-Phosphate Glucosephosphate Dehydrogenase Hepatobiliary Disorder Homo sapiens Ketoconazole Mephenytoin Microsomes, Liver Midazolam miglitol NADP Pharmaceutical Preparations Phenacetin Quinidine Sodium
5
In Vitro Cytochrome P450 Assay
Potassium phosphate buffer (200 µl, 0.1 M, pH 7.4) containing 1 mM NADPH, 0.5 mg/mL human liver microsomes, and a cocktail assay of seven probe substrates (Phenacetin for CYP1A2, Paclitaxel for CYP2C8, Tolbutamide for CYP2C9, Omeprazole for CYP2C19, Dextromethorphan for CYP2D6, Chlorzoxazone for CYP2E1, Dextromethorphan and Testosterone for CYP3A) or a single substrate (≤Km) were incubated at 37°C for 15 min (Supplementary Table S1). The contents of organic solvent and DMSO in incubation mixture was under 1% (v/v) and 0.1% (v/v) respectively. Reactions were terminated by adding 200 µL of an ice-cold stop solution consisting of methanol containing Rutin (2 µg/ml) as internal standard. Samples were subsequently cooled in ice bath to precipitate proteins. Supernatants were collected into clean tubes after centrifugation at 12000 rpm at 4°C for 10 min prior to inject into LC-MS/MS.
Lin F., Lin X., Wang X., Mei G., Chen B., Yao H, & Huang L. (2023). Inhibitory effect of Selaginella doederleinii hieron on human cytochrome P450. Frontiers in Pharmacology, 14, 1108867.
Full text: Click here
Publication 2023
Bath Biological Assay Buffers Centrifugation Chlorzoxazone Cold Temperature CYP1A2 protein, human CYP2C8 protein, human CYP2C19 protein, human Cytochrome P-450 CYP2D6 Cytochrome P-450 CYP2E1 Dextromethorphan Homo sapiens Methanol Microsomes, Liver NADP Omeprazole Paclitaxel Phenacetin potassium phosphate Proteins Rutin Solvents Sulfoxide, Dimethyl Tandem Mass Spectrometry Testosterone Tolbutamide

Top products related to «Dextromethorphan»

1
Dextromethorphan by Merck Group
Sourced in United States, Germany, Sao Tome and Principe
Dextromethorphan is a laboratory chemical compound used as a research tool. It is a dissociative anesthetic and cough suppressant. Dextromethorphan is commonly used in scientific research, but its specific applications and intended uses should not be extrapolated or interpreted beyond its core function as a laboratory product.
2
Phenacetin by Merck Group
Sourced in United States, China, Germany, United Kingdom, Poland
Phenacetin is a chemical compound used in the manufacturing of various pharmaceutical and laboratory products. It serves as a key ingredient in the production process. Phenacetin has specific functional properties that make it a valuable component in relevant applications, but a detailed description of its core function is beyond the scope of this response.
3
Chlorzoxazone by Merck Group
Sourced in United States, China, Germany, United Kingdom, Czechia
Chlorzoxazone is a laboratory chemical used as a reference standard. It is a crystalline solid with a molecular formula of C7H5ClNO. Chlorzoxazone is primarily used for analytical purposes and quality control in various industries.
4
Quinidine by Merck Group
Sourced in United States, Germany, China, Japan, France
Quinidine is a pharmaceutical compound used as a laboratory reagent. It is a diastereomer of the alkaloid quinine and has a chemical structure that allows it to be used in various biochemical and analytical applications.
5
Diclofenac by Merck Group
Sourced in United States, Germany, United Kingdom, France, Italy, Switzerland, Czechia, Sweden, Mexico
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that is used as a pain reliever and anti-inflammatory agent. It is a commonly used pharmaceutical ingredient in various lab equipment and medical products.
6
Sulfaphenazole by Merck Group
Sourced in United States, China, Germany
Sulfaphenazole is a laboratory reagent used in chemical synthesis and analysis. It is a sulfonamide compound with molecular formula C₁₄H₁₁N₃O₂S. Sulfaphenazole is commonly used as an analytical standard and in various organic reactions.
7
Acetaminophen by Merck Group
Sourced in United States, Germany, China, United Kingdom, Canada, Italy, Japan, Switzerland, France
Acetaminophen is a chemical compound used in the production of various pharmaceutical and laboratory products. It is a white, crystalline solid that is soluble in water and alcohol. Acetaminophen is a common active ingredient in over-the-counter pain and fever-reducing medications.
8
Glucose 6 phosphate dehydrogenase by Merck Group
Sourced in United States, Germany, China, Canada, Macao, Australia, Sao Tome and Principe
Glucose-6-phosphate dehydrogenase is an enzyme that catalyzes the conversion of glucose-6-phosphate to 6-phosphoglucono-δ-lactone, the first step of the pentose phosphate pathway. This enzyme plays a crucial role in maintaining cellular redox balance and generating NADPH, which is essential for various cellular processes.
9
Furafylline by Merck Group
Sourced in United States, China
Furafylline is a laboratory compound used as a research tool. It is a selective inhibitor of the CYP1A2 enzyme, which is involved in the metabolism of various drugs and other substances. Furafylline is utilized in studies to investigate the role of CYP1A2 in drug interactions and pharmacokinetics.
10
Ketoconazole by Merck Group
Sourced in United States, Germany, India, Sao Tome and Principe, United Kingdom, Macao, Israel
Ketoconazole is a laboratory product manufactured by Merck Group. It is an antifungal agent used for research and development purposes. The core function of Ketoconazole is to inhibit the synthesis of ergosterol, a key component of fungal cell membranes.

More about "Dextromethorphan"

Dextromethorphan (DXM) is a synthetic cough suppressant with dissociative properties, acting as an NMDA receptor antagonist to modulate glutamatergic neurotransmission and produce psychoactive effects.
It is a non-opioid drug with therapeutic applications that are actively being researched.
PubCompare.ai is an AI-driven platform that helps researchers locate and compare protocols for dextromethorphan from literature, preprints, and patents.
This tool can identify the most accurate and effective dextromethorphan protocols, streamlining the research process and enabling researchers to find the best dextromethorphan products.
In addition to dextromethorphan, other medications with similar mechanisms of action include phenacetin (a pain reliever and fever reducer), chlorzoxazone (a muscle relaxant), quinidine (an antiarrhythmic drug), diclofenac (a nonsteroidal anti-inflammatory drug), and sulfaphenazole (an antibacterial agent).
Acetaminophen, a common pain reliever, and glucose-6-phosphate dehydrogenase, an enzyme involved in cellular metabolism, are also relevant to dextromethorphan research.
Furafylline and ketoconazole are examples of inhibitors that can affect the metabolism and pharmacokinetics of dextromethorphan, making them important considerations in dextromethorphan research and clinical use.
By utilizing the insights and tools provided by PubCompare.ai, researchers can optimize their dextromethorphan studies and streamline the discovery of new therapeutic applications for this versatile compound.